Trial intelligence / Profile preview

MOSAIC

2024-514014-13-00Phase 2Authorised

Sponsor: Technische Universität Dresden
Start: Nov 2024
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised trial of midostaurin and gemtuzumab ozogamicin in acute myeloid leukemia (AML) (5 arms), sponsored by Technische Universität Dresden. Primary endpoints: Maximum tolerated dose (MTD) of midostaurin and gemtuzumab ozogamicin in combination, Event-free survival in core-binding factor AML (MAGNOLIA) and 1 more. Planned start Nov 2024; status: authorised.

Drugs

midostauringemtuzumab ozogamicin

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on 2024-514014-13-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-514014-13-00.